Executive Summary
Today's digest reveals a market bifurcated between aggressive capital deployment and mounting regulatory/operational risks. The most significant theme is a wave of transformative M&A and strategic pivots, highlighted by argenx's $2.2B acquisition of Forte Biosciences (86% premium) and NIMU's pivot to space via Gravitics.
However, this activity is juxtaposed against severe regulatory actions, most notably Trip.com's $763M penalty from China's SAMR, and a string of failed or abandoned deals (Onfolio/Paramount, IMAQ's 20th extension). Financial results are mixed: Ensign Group posted strong 17.3% revenue growth and raised guidance, while Ladder Capital saw net income fall 15.8% YoY. Insider activity is sparse but notable, with United Therapeutics' CEO selling $1.45M and Greenwich LifeSciences' CEO making small insider purchases. The forward-looking landscape is rich with catalysts, including AstraZeneca's mixed Phase III readouts and Apnimed's upcoming IPO, suggesting a high-conviction but risk-aware environment.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: 8-K · 13F · DEFA14A · 10-Q · Form 4 · 425 · S-1
Tracking the trend? Catch up on the prior US SEC Filings Daily Market Digest digest from July 24, 2026.
Investment Signals (11)
-
argenx acquiring Forte for $77/share (86% premium) adds FB102 (anti-CD122) with Phase 1b proof-of-concept in vitiligo and celiac. Transaction funded from cash, expected close Q3 2026. argenx's pipeline deepens with a first-in-class asset; Forte shareholders get a substantial premium. [BULLISH for argenx pipeline, BULLISH for Forte shareholders]
- Ensign Group ↓ (BULLISH)▲
Q2 2026 revenue grew 17.3% YoY to $1.44B, adjusted EPS up 20.8% YoY to $1.92. Full-year EPS guidance raised to $7.75-7.85 (midpoint +18.7% vs 2025). Over 80% of facilities have 4-5 star CMS ratings. Strong operational execution and positive outlook.
- Baker Hughes ↓ (BULLISH)▲
Q2 2026 adjusted EBITDA of $1,231M beat guidance and grew 6% sequentially, driven by IET orders doubling YoY to $7.1B and a record IET RPO of $37.1B. Total company book-to-bill was 1.6. Strong long-cycle backlog provides visibility.
- Trip.com Group ↓ (BEARISH)▲
Hit with a massive $763M penalty (RMB 5.18B) from China's SAMR for anti-monopoly violations, including a fine of 7.5% of 2025 PRC sales. The company accepts the decision, but the cash outflow and regulatory overhang are significant.
- United Therapeutics ↓ (BEARISH)▲
Chairperson & CEO Martine Rothblatt sold $1.45M in stock (2,719 shares at ~$532) under a 10b5-1 plan. While pre-planned, the magnitude of the sale (largest single transaction) may signal a desire to lock in gains near highs.
- Ladder Capital Corp ↓ (BEARISH)▲
Q2 2026 net income fell 15.8% YoY to $14.6M; H1 2026 net income down 40.9% YoY. Total costs and expenses rose 16.5% YoY, outpacing revenue growth. Dividend and buyback activity is pressuring equity.
- Clean Energy Technologies ↓ (BEARISH)▲
Q1 2026 revenue surged 77% YoY, but gross profit flipped to a loss of $13,930 from a $411,878 profit, as COGS skyrocketed. Cash plummeted 94% to $39K. The revenue growth is not translating to profitability.
-
FY26 record results (Revenue $27.9B, Adj. EPS $3.30) and proposed CPI spin-off. CEO supplemental award tied to CPI/data center growth has added $26.7B in market cap. However, CEO's near-retirement eligibility and limited retention value of awards are flagged as leadership risks. [MIXED - BULLISH on spin-off, BEARISH on leadership continuity]
- Sanofi ↓ (BEARISH)▲
Decision not to submit amlitelimab for global regulatory reviews in atopic dermatitis is a significant pipeline setback. This removes a key near-term catalyst and raises questions about the broader pipeline.
- AstraZeneca (Sone-Ve)▲
Positive Phase III for sonesitatug vedotin in gastric/GEJ cancers, meeting dual primary OS endpoint in 3rd/later-line and key secondary OS in 2nd/later-line. However, the PFS dual primary endpoint was not met. Mixed data but clinically meaningful OS benefit supports regulatory filings. [MIXED - BULLISH on OS data, BEARISH on PFS miss]
- AstraZeneca (Ultomiris)▲
Phase III trial in HSCT-TMA missed primary endpoint (event-free survival), but a separate pediatric trial showed 87.2% OS at 26 weeks. Regulatory path is bifurcated; adult indication faces headwinds. [BEARISH for adult indication, BULLISH for pediatric]
Risk Flags (9)
- Trip.com Group/Regulatory↓ [HIGH RISK]▼
Hit with a record $763M penalty from China's SAMR for anti-monopoly violations. The fine (7.5% of PRC sales) and required refunds/confiscation represent a massive cash outflow and signal heightened regulatory risk for Chinese internet platforms.
- Onfolio Holdings/Deal Failure↓ [MODERATE RISK]▼
Terminated LOI to acquire Paramount Helium just 14 days after signing. Mutual termination with no penalties suggests due diligence uncovered fatal issues. Raises questions about management's acquisition strategy and deal execution capability.
- ▼
Extended business combination deadline for the 20th time (out of 24 permitted). No target announced after nearly 20 months. High risk of liquidation if a deal is not consummated in the next 4 months.
- Clean Energy Technologies/Cash Burn↓ [HIGH RISK]▼
Cash and cash equivalents plummeted 94% to just $39K from $602K at year-end 2025. Operating cash flow worsened to -$836K. The company is burning cash rapidly with no path to profitability, raising going-concern risks.
- Ladder Capital Corp/Earnings Decline↓ [MODERATE RISK]▼
Net income declined 15.8% YoY in Q2 and 40.9% in H1 2026. Costs are growing faster than revenue (16.5% vs 4.9% net interest income growth). Dividend and buybacks are depleting equity (down 3.7%).
-
Former auditor resigned due to strategic shift away from the sector. Company has a material weakness in internal control over financial reporting related to income taxes. Combined with going-concern doubts, this signals significant governance and financial reporting risks.
- Sanofi/Pipeline Setback↓ [MODERATE RISK]▼
Decision not to submit amlitelimab for atopic dermatitis removes a key pipeline catalyst. This could signal a lack of confidence in the data or a strategic shift, impacting the company's growth narrative in immunology.
- ▼
NIMU has an accumulated deficit of $44.3M, and its acquisition target Gravitics has a $13.8M deficit. Both are loss-making entities. The merger is a high-risk pivot into space with no clear path to profitability.
- Apnimed/Accumulated Losses↓ [MODERATE RISK]▼
Despite a Q1 2026 profit driven by one-time related-party revenue, the company has an accumulated deficit of $329.6M. The IPO comes after a year of $128.2M in net losses, suggesting the business is not yet self-sustaining.
Opportunities (9)
- argenx/Forte Biosciences Acquisition↓ (OPPORTUNITY)◆
The acquisition of FB102 (anti-CD122) adds a first-in-class asset with clinical proof-of-concept in vitiligo and celiac. Phase 2 celiac data expected H2 2026. argenx's cash-funded deal avoids dilution. Opportunity to gain exposure to a potential new blockbuster immunology asset.
- Ensign Group/Guidance Raise↓ (OPPORTUNITY)◆
Raised full-year 2026 EPS guidance to $7.75-7.85 (midpoint +18.7% vs 2025) and revenue to $5.87-5.92B. Strong operational metrics (80%+ 4-5 star facilities, improving RN retention) support continued outperformance.
- Baker Hughes/IET Backlog↓ (OPPORTUNITY)◆
Record IET RPO of $37.1B and a book-to-bill of 2.2 provide exceptional revenue visibility. The doubling of IET orders YoY signals strong demand for LNG and energy infrastructure. Opportunity to play the multi-year energy capex cycle.
- Flex Ltd./CPI Spin-off↓ (OPPORTUNITY)◆
The proposed spin-off of the Cloud & Power Infrastructure business is a value-unlocking catalyst. The CEO's at-risk supplemental award is tied to aggressive CPI/data center growth targets. The spin-off announcement alone added ~$8.5B (+24%) in value.
- AstraZeneca/Sone-Ve Regulatory Filings↓ (OPPORTUNITY)◆
Positive OS data in gastric/GEJ cancers supports regulatory filings. Orphan Drug Designation in US/EU and Breakthrough Designation in China could accelerate approvals. Opportunity in a high-unmet-need indication with a large addressable population (~60% of patients).
-
Targeting $134.6M in net proceeds from IPO of 10M shares at $15.00. The company has a dramatic Q1 2026 profit ($67.7M) driven by a $100M milestone payment. IPO proceeds will fund development of its sleep apnea portfolio. [OPPORTUNITY - but with high risk]
-
Favorable pre-clinical toxicology results support advancement of NMRA-215. Positive safety data is a key derisking milestone for this neuroscience candidate. [OPPORTUNITY - early stage]
-
CEO/CFO Patel Snehal purchased 3,600 shares at ~$13 for ~$47K. While small, insider buying at current levels signals confidence in the company's prospects. [OPPORTUNITY - small signal]
- BBVA/Share Buyback (OPPORTUNITY)◆
Has executed 88.7% of the Third Tranche's maximum cash amount (€1.295B). The aggressive buyback pace signals strong capital return to shareholders and management's confidence in the balance sheet.
Sector Themes (6)
- Energy Infrastructure Boom◆
Baker Hughes' record IET RPO ($37.1B) and 2.2 book-to-bill, alongside Flex's CPI spin-off targeting data center growth, signal a multi-year investment cycle in energy infrastructure, particularly LNG and data centers. This theme is supported by strong order momentum and capital allocation towards the sector.
- Biotech M&A and Pipeline Catalysts◆
The day is dominated by biotech catalysts: argenx's $2.2B acquisition of Forte, AstraZeneca's two Phase III readouts (one positive, one mixed), Sanofi's pipeline setback, and Neumora's pre-clinical progress. This highlights a high-risk/high-reward environment where binary events drive significant valuation changes.
- Regulatory Risk in China◆
Trip.com's $763M penalty from SAMR is a stark reminder of the regulatory risks facing Chinese ADRs. This event, combined with the lack of material news from other Chinese filers (The9, Li Auto, Zhihu), suggests a cautious environment for the sector.
- Capital Return vs. Reinvestment◆
A clear divergence is visible. BBVA and Prudential are aggressively buying back shares, signaling confidence. In contrast, Ensign Group is balancing acquisitions ($376M) with buybacks ($40M), while Ladder Capital's buybacks and dividends are pressuring equity. This split reflects differing views on growth opportunities.
- SPAC and M&A Market Stress◆
The struggles of International Media Acquisition Corp. (20th extension) and the rapid failure of Onfolio's LOI (14 days) indicate a challenging environment for SPACs and small-cap M&A. Deals are falling through or taking much longer to execute, signaling higher due diligence standards or valuation gaps.
- Mixed Healthcare Earnings Signals◆
Ensign Group (skilled nursing) shows strong growth, while Ladder Capital (healthcare REIT) shows earnings declines. This suggests a sub-sector divergence within healthcare, where operational excellence (Ensign's CMS ratings) is rewarded, but broader real estate exposure (Ladder) faces headwinds from rising costs.
Watch List (9)
-
Transaction expected to close Q3 2026. Watch for shareholder votes and any regulatory hurdles. Also watch for Phase 2 celiac data for FB102 in H2 2026.
-
Watch for the impact of the $763M penalty on Q3 2026 cash flow and any further regulatory actions. The company's acceptance of the decision may lead to governance changes.
- Apnimed IPO👁
Expected to price soon. Watch for the final IPO price and first-day trading performance. The company's ability to raise capital will be a key test of investor appetite for development-stage biotech.
-
With only 4 extensions left (deadline now Sep 2, 2026), watch for any announcement of a target or a liquidation vote. This is a time-sensitive risk.
-
Watch for further details on the spin-off, including the tax-free structure and the valuation of SpinCo. The CEO's performance award tied to CPI growth makes this a key catalyst to monitor.
- 👁
Watch for further details on the Executive Committee evolution and any strategic update following the amlitelimab decision. The company's next pipeline event will be closely scrutinized.
- AstraZeneca (Ultomiris)👁
Watch for regulatory discussions with health authorities regarding the adult HSCT-TMA data and the planned filing for the pediatric indication. The outcome will determine the commercial opportunity.
-
CEO Ying Huang resigned effective July 24. Interim CEO Alan Bash (President of CARVYKTI) is in place. Watch for the appointment of a permanent CEO and any strategic shifts in the CARVYKTI commercial launch.
-
Special meeting to vote on the merger. Record date is July 29, 2026. Watch for shareholder approval and the subsequent listing of the combined entity.
Filing Analyses
(50)
27-07-2026
Non-Invasive Monitoring Systems Inc. (NIMU) filed an S-4/A registration statement related to its acquisition of Gravitics Inc., a space technology company. The filing includes financial statements for both entities, showing NIMU's parent company with significant accumulated deficits and Gravitics as an early-stage company with minimal revenue and substantial losses. The merger represents a strategic pivot into the space industry, but both companies exhibit weak financial positions with ongoing net losses.
- · NIMU parent company had an accumulated deficit of approximately $44.3 million as of March 31, 2026.
- · Gravitics Inc. had an accumulated deficit of approximately $13.8 million as of December 31, 2025.
- · NIMU's net loss for the three months ended March 31, 2026 was approximately $0.2 million.
- · Gravitics Inc. reported a net loss of approximately $3.5 million for FY2025.
- · The filing includes promissory notes from related parties (Frost Gamma Investments Trust and Dr. Jane Hsiao) totaling approximately $1.5 million as of March 31, 2026.
- · NIMU's total stockholders' equity was approximately $1.2 million as of March 31, 2026, down from $1.4 million as of December 31, 2025.
- · Gravitics Inc. had total stockholders' equity of approximately $2.1 million as of December 31, 2025.
27-07-2026
Profusa, Inc. announced the signing of a non-binding term sheet to acquire a privately held commercial-stage diagnostics company (the 'Dx Company') with estimated 2025 net revenues of approximately $111 million. Concurrently, Jack Stover was appointed Executive Chairman and CEO, replacing Ben Hwang who became President, and Liviu Goldenberg was appointed as an independent director. The transaction is expected to close with Profusa issuing 19.99% of its common stock and non-voting convertible preferred stock as consideration, along with approximately $7 million in convertible note financing.
- · The Dx Company is a commercial-stage health diagnostics and toxicology testing company with CLIA-certified and CAP/CLIA accredited national medical laboratories.
- · The Dx Company serves addiction treatment, pain management, and behavioral health providers.
- · Profusa's outstanding convertible notes and obligations are expected to be exchanged for Preferred Stock.
- · The convertible note financing is subordinated to existing bank debt and has a 12-month term.
- · Existing investors in Profusa may provide all or portions of the $7 million financing.
27-07-2026
The9 Limited filed a Form 6-K with the SEC for July 2026, announcing a record quarterly profit for the three months ended March 31, 2026, and expects sequential growth through the remainder of the year. The filing also discloses the appointment of George Lai as Chief Executive Officer. No negative or flat financial metrics are mentioned in the filing, but the forward-looking statement about sequential growth implies a positive outlook.
- · The filing incorporates by reference into the registration statement on Form F-3 (File No. 333-295089).
- · Exhibits include an awareness letter from RBSM LLP, a press release on record quarterly profit, management's discussion and analysis for Q1 2026, and a report of independent registered public accounting firm.
27-07-2026
Ensign Group reported strong Q2 2026 results with GAAP diluted EPS of $1.68 (+16.7% YoY) and adjusted EPS of $1.92 (+20.8% YoY). Consolidated revenue grew 17.3% YoY to $1.44 billion. However, the newly acquired facilities have lower occupancy than existing operations and present clinical and operational hurdles, indicating mixed near-term performance despite overall positive momentum. The company raised its full-year 2026 EPS guidance to $7.75–$7.85 (midpoint +18.7% vs. 2025) and revenue guidance to $5.87–$5.92 billion.
- · Over 80% of skilled nursing operations earned a CMS Quality Measure rating of 4 or 5 stars.
- · None of the 398 affiliated facilities are designated as CMS Special Focus Facilities.
- · Director of Nursing turnover continues to improve; RN retention rate is 8% better than average across footprint.
- · Company acquired 20 new operations (all with real estate assets) in the quarter, primarily in Texas and other states, with occupancies lower than existing operations and presenting clinical/operational hurdles.
- · Standard Bearer generated rental revenue of $44.1M for the quarter, of which $37.8M was from Ensign-affiliated operations.
- · Guidance assumes 25.0% tax rate, ~59.5M diluted shares, normalized insurance costs, and acquisitions expected to close through Q3 2026.
- · Midpoint of raised EPS guidance ($7.80) represents 18.7% increase over 2025 and 41.8% over 2024.
- · Dividend of $0.065 per share paid in the quarter.
27-07-2026
Baker Hughes reported Q2 2026 revenue of $6.7B, up 2% sequentially but down 2% YoY, with GAAP net income of $681M (down 27% sequentially and 3% YoY). Adjusted EBITDA of $1,231M exceeded guidance and grew 6% sequentially and 2% YoY, driven by strong IET orders ($7.1B, doubling YoY) and record IET RPO of $37.1B. However, GAAP EPS fell 27% sequentially to $0.68, and revenue declined YoY due to business dispositions, while OFSE RPO remained flat sequentially at $3.0B.
- · IET book-to-bill ratio was 2.2; total company book-to-bill was 1.6.
- · OFSE RPO remained flat sequentially at $3.0B.
- · GAAP net income declined 27% sequentially and 3% YoY, while adjusted net income grew 12% sequentially and 3% YoY.
- · Cash flow from operations surged to $1,345M from $500M in Q1 2026 and $510M in Q2 2025.
- · Free cash flow was $1,109M, up from $210M in Q1 2026 and $239M in Q2 2025.
- · Other income included a $125M net gain from change in fair value of equity securities, partially offset by $30M in transaction costs and $24M working capital adjustments.
- · Income tax expense was $210M.
- · Depreciation and amortization was $333M.
- · The company completed the acquisition of Chart Industries in July 2026.
- · The company announced the sale of Waygate Technologies to Hexagon for ~$1.45B.
- · IET secured a major award from Venture Global for 6 LNG blocks (12 liquefaction modules).
- · IET received awards from Cheniere and Bechtel for Sabine Pass Train 7 and fleet upgrades, supporting ~6 MTPA additional LNG capacity.
- · IET received a significant award from Golar for a 3.5 MTPA floating LNG facility.
- · IET secured a major award from Dynamis Power Solutions for 76 NovaLT16 gas turbines (~1.3 GW).
- · IET signed a multi-year agreement with Kodiak Gas Services for up to 1.8 GW of power generation capacity.
- · OFSE secured a major contract extension with Petrobras for integrated well construction in Brazil's Santos Basin.
- · OFSE signed contracts with ONGC for 46 advanced wireline units and integrated drill stem testing kits.
- · OFSE received a substantial subsea production systems contract from Azule Energy for ultra-deepwater development offshore Angola.
- · OFSE won a significant contract from McDermott for subsea systems offshore Brunei Darussalam.
- · The company advanced geothermal development with Mantle Reach Power (target up to 500 MW in 5 years).
- · Leucipa platform was deployed for the first time outside oil & gas, for a geothermal and lithium extraction project in Europe.
- · OFSE signed a strategic collaboration with Helmerich & Payne for geothermal exploration in the US.
- · IET received RINA certification for NovaLT16 for maritime propulsion (up to 100% hydrogen).
- · IET grew digital solutions with agreements from SINOPEC, Petrobras, and KNPC.
27-07-2026
ICICI Bank Limited disclosed that Moody's Ratings and S&P Global Ratings have assigned 'Baa3' and 'BBB' ratings, respectively, to its USD-denominated Senior Unsecured Fixed Rate Notes issued under its Global Medium Term Note Programme through its IFSC Banking Unit. The notes are not being offered in the United States. The filing contains no financial performance data or period-over-period comparisons.
- · Moody's assigned a 'Baa3' rating to the Notes.
- · S&P Global Ratings assigned a 'BBB' rating to the Notes.
- · The Notes are issued under ICICI Bank's Global Medium Term Note Programme through its IFSC Banking Unit.
- · The Notes are not registered under the U.S. Securities Act of 1933 and are not offered for sale in the United States.
27-07-2026
Shengqi Capital (Hong Kong) Ltd filed its quarterly 13F-HR for the period ending June 30, 2026, reporting total holdings of approximately $483.7 million across 12 positions. The fund's largest disclosed holdings include Micron Technology ($219.3M), Qualcomm ($168.3M combined across common stock and call options), and Meta Platforms ($22.5M in put options). The portfolio shows a concentrated technology focus with significant use of options strategies, including puts on Alphabet, Meta, Microsoft, and SpaceX, as well as a large call position on Qualcomm.
- · The fund holds a significant put option position on Space Exploration Technologies Corp (SpaceX), valued at $11.4M, indicating a bearish or hedging stance on the private space company.
- · Qualcomm is the only position with both common stock ($76.2M) and call options ($92.0M), suggesting a bullish outlook on the stock.
- · The fund's smallest positions include Greenland Mines ($26), iShares Bitcoin Trust ($3.3K), and Alphabet Class C common ($35.3K), which may be residual or symbolic holdings.
- · No period-over-period comparisons are available as this is the fund's initial 13F filing (no prior quarter data provided).
27-07-2026
Ericsson announced a share buyback program for the period July 20-24, 2026, as part of its ongoing capital return to shareholders. The report covers a single week of repurchases. No financial figures beyond the announcement are provided in the filing.
- · The buyback period covered is July 20 to July 24, 2026.
- · The filing is made under Form 6-K for SEC reporting purposes.
27-07-2026
Radiopharm Theranostics Ltd filed a Form 6-K with the SEC on July 27, 2026, disclosing the terms of a warrant exercise. The exercise price per ADS is set at $3.79, with the exercise price determined by a formula based on the volume-weighted average price (VWAP) or bid price at the time of exercise.
- · The exercise price is subject to adjustment under the warrant terms.
- · The VWAP calculation depends on the timing of the Notice of Exercise relative to trading hours and Trading Days.
27-07-2026
argenx (ARGX) will acquire Forte Biosciences (FBRX) for $77 per share in cash, representing a total equity value of approximately $2.2 billion and an 86% premium to Forte's VWAP since its positive Phase 1b vitiligo data on July 9, 2026. The acquisition adds FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease, to argenx's immunology pipeline. The transaction is expected to close in Q3 2026, funded entirely from cash on hand, and has been approved by both boards.
- · FB102 Phase 1b data in vitiligo showed statistically significant treatment benefit.
- · Positive FB102 Phase 1b data in celiac disease was shared last year; Phase 2 data expected in second half of 2026.
- · FB102 has potential to address alopecia areata and additional autoimmune diseases.
- · The tender offer requires at least a majority of outstanding shares tendered and HSR Act waiting period expiration.
- · Transaction is not subject to a financing condition.
- · argenx will host an investor conference call at 8:00 a.m. ET on July 27, 2026.
27-07-2026
Li Auto Inc. filed a Form 6-K with the SEC for July 2026, attaching five Next Day Disclosure Returns dated July 20-24, 2026. The report is a routine foreign issuer filing and does not contain any financial results or material operational updates.
- · Filing includes Next Day Disclosure Returns for five consecutive days: July 20, 21, 22, 23, and 24, 2026.
- · The report is signed by Tie Li, Director and CFO, on July 27, 2026.
27-07-2026
Flex Ltd. filed a DEFA14A proxy solicitation material highlighting a record FY26 (Revenue $27.9B, Adj. operating income $1.8B, Adj. EPS $3.30) and a proposed spin-off of its Cloud & Power Infrastructure (CPI) business into a separate public company (SpinCo). The filing details a June 2025 CEO supplemental equity award designed to drive CPI/data center growth, noting that since the award Flex shareholders have seen $26.7B in market value appreciation and the spin-off announcement itself added ~$8.5B (+24%) in value. While results are exceptionally strong, the filing contains no prior-period comparative financial data for the spin-off or the CEO award's performance targets, and the CEO's near-retirement eligibility and limited retention value of outstanding awards are flagged as risks to leadership continuity.
- · The CEO supplemental award is 100% at-risk; target funding is set more than 20% above the company's long-term plan for CPI/data center operating profit.
- · Payout capped at 200% of target if relative TSR is below median; capped at 100% of target if relative TSR is below 25th percentile.
- · CEO's outstanding equity awards would have limited retention value shortly after grant, and the supplemental award is not eligible for enhanced retirement treatment.
- · Shareholders are asked to vote on re-appointment of independent auditors, advisory say-on-pay, authorization of ordinary share issuances, and renewal of share purchase mandate at the 2026 AGM.
27-07-2026
Lufax Holding Ltd filed a Form 6-K with the SEC for July 2026, including an announcement to the Stock Exchange of Hong Kong Limited regarding a list of directors and their roles and functions. The report was signed by CEO Xiang Ji. No financial results, quantitative data, or material operational updates were provided.
- · Filing date: July 27, 2026
- · Commission file number: 001-39654
- · Exhibit 99.1 contains an announcement regarding list of directors and their roles and functions
27-07-2026
Antero Midstream Corp filed an 8-K to furnish a press release announcing the redemption of its outstanding 5.75% Senior Notes due 2028. The redemption is being made solely pursuant to the Notice of Redemption dated July 24, 2026. The filing is a Regulation FD disclosure and is not deemed filed under the Exchange Act.
- · The filing is under Item 7.01 (Regulation FD Disclosure) and is not deemed filed under Section 18 of the Exchange Act.
- · The redemption is being made solely pursuant to the Notice of Redemption dated July 24, 2026.
27-07-2026
ARGENX SE filed a Form 6-K with the SEC on July 27, 2026, attaching a press release issued the same day. The filing does not disclose any financial results, material events, or performance metrics, and no quantitative data is provided.
- · The press release is incorporated by reference into the Company's Registration Statements on Forms S-8 (File Nos. 333-225375, 333-258253, 333-274721, and 333-292200).
27-07-2026
HDFC Bank Ltd filed a Form 6-K with the SEC for July 2026, signed by Company Secretary Ajay Agarwal. The filing is a routine periodic report and does not contain any financial results, material events, or operational updates.
- · Filing is a Form 6-K for the month of July 2026.
- · No financial data, business updates, or material events were disclosed in this filing.
- · The registrant files annual reports under Form 20-F.
27-07-2026
Ensign Group reported strong Q2 2026 results with total revenue of $1.44B, up 17.3% YoY, and net income attributable to the company of $99.7M, up 18.2% YoY. For the first half of 2026, revenue grew 17.9% to $2.83B and net income rose 21.1% to $199.4M. However, cash and cash equivalents declined sharply by 48.0% from $503.9M at year-end 2025 to $262.3M, driven by $376.0M in acquisition spending and $40.0M in share repurchases during the first half of 2026.
- · Medicaid revenue was the largest payor source at 39.6% of service revenue in Q2 2026, up 16.7% YoY to $566.8M.
- · Medicare revenue grew 16.7% YoY to $339.7M in Q2 2026, representing 23.7% of service revenue.
- · Managed care revenue increased 15.6% YoY to $265.3M in Q2 2026, accounting for 18.5% of service revenue.
- · Private and other revenue grew 28.8% YoY to $180.0M in Q2 2026, the fastest-growing payor segment.
- · Total assets increased 5.2% to $5.75B as of June 30, 2026 from $5.46B at December 31, 2025.
- · Long-term debt (less current maturities) was $135.6M, relatively flat compared to $137.5M at year-end 2025.
- · Goodwill remained unchanged at $98.0M, indicating no impairment charges.
- · Dividends declared were $0.0650 per share in both Q1 and Q2 2026, totaling $7.6M paid in H1 2026.
- · Accrued self-insurance liabilities (current and long-term) increased 27.6% to $295.8M from $246.4M at year-end 2025.
- · Accounts receivable grew 5.0% to $668.9M, with allowance for doubtful accounts of $7.9M.
27-07-2026
International Media Acquisition Corp. (IMAQW) extended its deadline to complete an initial business combination by one month, from August 2, 2026 to September 2, 2026, by depositing $2,000 into its trust account. This is the 20th of 24 permitted monthly extensions, indicating the company has been unable to consummate a merger for nearly 20 months and is running low on available extensions. The filing does not disclose any new target or progress toward a deal.
- · The extension moves the deadline from August 2, 2026 to September 2, 2026.
- · This is the 20th extension letter out of a total of 24 permitted under the Trust Agreement.
- · The trust agreement was originally dated July 28, 2021 and has been amended multiple times (July 26, 2022; January 27, 2023; July 31, 2023; January 2, 2024; December 31, 2024).
- · The company's securities (IMAQ, IMAQW, IMAQR, IMAQU) are not listed on any exchange (trading symbol column shows 'None').
27-07-2026
On July 25, 2026 Trip.com Group Limited received an administrative penalty Decision from the State Administration for Market Regulation (SAMR) finding violations of Article 22(4) and (5) of China’s Anti-Monopoly Law. SAMR ordered cessation of the violations and (i) full refund of RMB122 million (US$18.0 million) in hotel order security deposits, (ii) confiscation of gains of RMB1,658 million (US$244.4 million), and (iii) a fine of RMB3,521 million (US$518.9 million) equal to 7.5% of Trip.com’s PRC sales revenue in 2025. The Company accepts the Decision and will implement rectification and governance measures. While the company presents acceptance and remedial intent (positive governance signal), the ruling imposes substantial cash outflows and reputational/regulatory risk (negative impact).
- · SAMR found violations of Article 22(4) and (5) of China’s Anti-Monopoly Law (restricting counterparties via exclusive arrangements and imposing unreasonable transaction terms).
- · All RMB-to-USD translations in the filing use exchange rate RMB6.7851 to US$1.00 (as of June 30, 2026 per FRB H.10).
- · The fine of RMB3,521 million is explicitly described as representing 7.5% of the Company’s PRC sales revenue in 2025.
- · The Decision was issued on July 25, 2026; the Company announced SAMR’s investigation originally on January 14, 2026.
27-07-2026
Legend Biotech Corporation announced the resignation of CEO Ying Huang effective July 24, 2026, with no disagreement with the company. The Board appointed Alan Bash, President of CARVYKTI since October 2024, as Interim CEO and interim principal executive officer. The company has initiated a search for a permanent CEO.
- · Ying Huang's resignation was effective July 24, 2026, and he will serve as an advisor through August for transition.
- · Alan Bash was appointed Interim CEO on July 23, 2026, effective July 24, 2026.
- · Alan Bash has served as President of CARVYKTI since October 2024.
- · No related party transactions or family relationships between Alan Bash and the company's directors or executive officers.
- · The company has initiated a search for a permanent CEO.
27-07-2026
AITX filed an 8-K on July 27, 2026, announcing a press release outlining its product development roadmap targeting six hardware releases and nine software initiatives. The filing is a routine update on future product plans and does not include any financial results or performance metrics.
- · Press release titled 'AITX Outlines Product Development Roadmap Targeting Six Hardware Releases and Nine Software Initiatives' was issued on July 27, 2026.
- · The filing is furnished under Item 8.01 and is not deemed 'filed' for Exchange Act purposes.
27-07-2026
SemiLEDs Corp announced a change in its independent registered public accounting firm. YCM CPA INC. engagement expired on July 27, 2026, and the audit committee engaged DLEE Accountancy, Inc. as the new auditor. There were no disagreements or reportable events with the former auditor.
- · No disagreements or reportable events occurred with YCM during the most recent fiscal year and through the expiration date.
- · The company has not consulted DLEE on any accounting, auditing, or financial reporting issues prior to engagement.
27-07-2026
Southern California Gas Company (SoCalGas) is urging shareholders to vote before the August 6, 2026 Special Meeting to approve a proposal to retire two outstanding classes of preferred stock for a cash payment. The Board and independent proxy advisor Glass Lewis recommend voting 'FOR' the proposal, which offers a premium of more than 20% over recent market prices, estimated fair value, and par value. The filing does not disclose any financial results or performance metrics, so no period-over-period comparisons are available.
- · Special Meeting date: August 6, 2026
- · Deadline to vote is approaching as of July 27, 2026
- · Proposal aims to simplify capital structure by retiring two outstanding classes of preferred stock
- · Trading prices of preferred stock have materially declined in recent years with low liquidity and high brokerage fees
- · Internet and telephone voting available via proxyvote.com
- · Assistance available from D.F. King & Co., Inc. at (800) 769-7666
27-07-2026
Veraxa Biotech AG held an Extraordinary General Meeting on July 24, 2026, where shareholders approved amendments to the Articles of Association, including conditional share capital for options/warrants, a capital band through 2030, and an expanded board (from five to seven members). The company also announced key leadership changes: Carl von Halem as Interim CFO (succeeding Torsten Bürgermeister) and Christoph Erkel, Ph.D., as Chief Scientific Officer (succeeding Rick Austin, Ph.D.). Additionally, Veraxa provided updates on its BiTAC-TCE program, including initiation of cell line development and regulatory progress, as well as details on its partnering strategy and development timelines. No financial figures or performance metrics were disclosed in this filing.
- · The company refiled certain information previously filed under an incorrect CIK filer number (CIK 0002079364) on July 6, 10, 20, and 23, 2026.
- · Record date for the EGM was July 20, 2026.
- · Carl von Halem also serves as CFO of Xlife Sciences AG (since December 2021), Managing Director of Xlife Sciences GmbH (since February 2022) and XRNA Biotech GmbH (since January 2023), Board Member of Axenoll Life Sciences AG (since June 2025) and FUSE-AI AG (since August 2025), and Co-Founder/COO of CommneX GmbH (since 2016).
- · Christoph Erkel previously served as Vice President of R&D at Veraxa and as Research Program Leader at MorphoSys AG.
- · The company changed its name from Veraxa Biotech Holding AG to Veraxa Biotech AG.
27-07-2026
Zhihu Inc. filed a Form 6-K with the SEC for July 2026, attaching Next Day Disclosure Returns from July 17-24, 2026. The filing is a routine foreign issuer report with no financial results or material events disclosed.
- · Filing includes six Next Day Disclosure Returns dated July 17, 20, 21, 22, 23, and 24, 2026.
- · No financial data or operational updates are provided in the filing.
27-07-2026
Balchem Corporation entered into Amendment No. 1 to its Amended and Restated Credit Agreement, effective July 24, 2026, which amends the existing credit facility, adds a new foreign borrower (Balchem B.V.), and replaces a departing lender (KeyBank National Association). The amendment also reallocates commitments among lenders and includes new lenders. No financial figures or performance metrics are disclosed in this filing.
- · The amendment adds Balchem B.V. (Netherlands) as a new foreign borrower under the credit agreement.
- · KeyBank National Association is departing as a lender; its loans are repaid in full and its commitments terminated.
- · New lenders join the facility, and commitments are reallocated among all lenders.
- · The amendment modifies several schedules and exhibits of the existing credit agreement (Schedules 2.01A, 2.01B, 6.09, 6.13, 6.17, 6.20-1, 6.20-2, 8.02, 11.02 and exhibits).
27-07-2026
On July 21, 2026, Onfolio Holdings Inc. and Paramount Helium, LLC mutually terminated their Binding Letter of Intent to acquire Paramount, originally signed on July 7, 2026. The termination was by mutual consent with no penalties or further financial obligations for either party. The deal fell through just two weeks after the LOI was signed, indicating a very short-lived acquisition attempt.
- · The LOI was signed on July 7, 2026, and terminated just 14 days later on July 21, 2026.
- · Confidentiality obligations under a Mutual Non-Disclosure Agreement dated June 10, 2026 survive the termination.
- · No termination penalties or financial obligations were incurred by either party; each bears its own costs.
- · A press release announcing the termination was issued on July 22, 2026.
27-07-2026
Papaya Growth Opportunity Corp. I disclosed that its former auditor, Citrin Cooperman & Company, LLP, declined to stand for re-election effective July 22, 2026, due to a strategic shift away from the company's sector. The audit committee has appointed Malone Bailey, LLP as the new independent registered public accounting firm. The change was not due to any disagreements on accounting principles, but the company had previously identified a material weakness in internal control over financial reporting related to income taxes.
- · The former auditor's reports for fiscal years ended December 31, 2024 and 2023 included an explanatory paragraph about substantial doubt regarding the company's ability to continue as a going concern.
- · A material weakness in internal control over financial reporting related to proper recording of income taxes was identified in the 2023 annual report and quarterly reports for March 31, 2025, June 30, 2025, and September 30, 2025.
- · No disagreements or reportable events occurred between the company and the former auditor during the relevant periods, aside from the material weakness noted.
27-07-2026
Swarmer, Inc. announced a promotion and realignment of its executive leadership team. Garrett Kasper was promoted to Chief Communications Officer, Serhii Kupriienko will lead a new innovation unit called Swarmer Labs, and CEO Alexander Fink's oversight was expanded to include HR, finance, and operations. The changes aim to balance short-term delivery with long-term innovation as the company scales.
- · Swarmer's technology has been deployed in combat operations in Ukraine since April 2024 and has completed more than 100,000 combat missions.
- · Garrett Kasper retired from the Navy Reserve on June 1, 2026, as a highly decorated captain.
- · Swarmer maintains operations and teams in Ukraine, Poland, and Estonia.
- · The company is not a drone manufacturer and operates at the intelligence layer, developing autonomy, coordination, and decision-making software.
27-07-2026
Twenty One Capital, Inc. (NYSE: XXI) filed an 8-K on July 27, 2026, reporting that its newly appointed CEO, Raphael Zagury, presented a fireside chat at the Mining Disrupt 2026 conference on July 22, 2026. Zagury outlined a strategic shift from a pure Bitcoin treasury model toward a 'Bitcoin operating company' inspired by Berkshire Hathaway, emphasizing disciplined capital allocation, investments in cash-flow-positive operating businesses (especially Bitcoin mining), and a decentralized management model. The filing includes a transcript of the chat as an exhibit, but provides no new financial data or performance metrics.
- · CEO Raphael Zagury was named CEO on July 21, 2026, the day before the fireside chat.
- · Zagury criticized the pure Bitcoin treasury model as a 'dislocation' that is converging toward net asset value, and advocated for investing in cash-flow-positive operating businesses.
- · He compared the strategy to Berkshire Hathaway's use of insurance float (e.g., GEICO) to generate cash for reinvestment, with Bitcoin mining serving a similar role.
- · The filing includes a cautionary note on forward-looking statements and a disclaimer about potential transcription errors.
- · No financial results, guidance, or quantitative performance data were provided in the filing.
27-07-2026
Ladder Capital Corp reported net income attributable to Class A common shareholders of $14.6M for Q2 2026, down 15.8% from $17.3M in Q2 2025. For the six months ended June 30, 2026, net income was $17.2M, a 40.9% decline from $29.1M in the prior year period. Total assets grew 8.8% to $5.61B, driven by increases in mortgage loan receivables and real estate investments, while total equity decreased 3.7% to $1.43B due to dividends and share repurchases.
- · Net interest income for Q2 2026 was $22.6M, up 4.9% from $21.5M in Q2 2025.
- · Total other income for Q2 2026 was $35.2M, up 1.3% from $34.7M in Q2 2025.
- · Total costs and expenses for Q2 2026 were $41.3M, up 16.5% from $35.5M in Q2 2025.
- · Basic and diluted EPS for Q2 2026 were $0.12, down from $0.14 in Q2 2025.
- · Book value per share (total equity / shares outstanding) as of June 30, 2026 was approximately $11.24.
- · Dividends declared in H1 2026 totaled $58.5M.
- · Share repurchases in H1 2026 were $21.5M.
- · Mortgage loan receivables held for investment increased 25.8% from Dec 31, 2025 to Jun 30, 2026.
- · Securities decreased 10.3% from Dec 31, 2025 to Jun 30, 2026.
- · Debt obligations increased 14.1% from Dec 31, 2025 to Jun 30, 2026.
27-07-2026
Chief Executive Officer Feng Dagang was awarded 58,787,000 Employee Share Option at $0.00 (~$5.88K). Trades executed under a Rule 10b5-1 plan.
- · Chief Executive Officer Feng Dagang was awarded 58,787,000 Employee Share Option at $0.00 (~$5.88K)
27-07-2026
Clean Energy Technologies, Inc. (CETY) reported a net loss of $662,200 for Q1 2026, nearly identical to the $660,058 loss in Q1 2025. Total revenue surged 77% YoY to $783,705, driven by a massive ramp in NG Trading ($776,167 vs $3,481), but this was offset by a gross loss of $13,930 compared to a gross profit of $411,878 in the prior year, as cost of goods sold skyrocketed to $797,635 from $30,062. Cash and cash equivalents plummeted 94% to just $39,078 from $602,461 at year-end 2025, while total assets grew to $13.9M and total liabilities increased to $6.9M.
- · Operating cash flow worsened to -$836,618 in Q1 2026 from -$776,047 in Q1 2025.
- · Investing activities used $702,746 in Q1 2026, primarily for a $700,000 convertible note receivable and a $2,746 long-term investment.
- · Financing activities provided $975,557 in Q1 2026, mainly from $1,336,469 in proceeds from notes payable and lines of credit, partially offset by $395,451 in payments.
- · Derivative liability increased to $721,678 from $493,308 at year-end 2025.
- · Convertible notes payable nearly doubled to $1,794,742 from $880,052.
- · Short-term notes payable decreased sharply to $171,821 from $722,350.
- · Interest and financing fees rose to $515,128 from $348,186.
- · Other income of $584,613 was recognized in Q1 2026, largely from a change in fair value of a convertible note receivable ($435,053).
- · Heat Recovery Solutions segment swung from a profit of $235,658 to a loss of $25,223.
- · Waste to Energy segment had zero revenue in Q1 2026 vs $176,105 in Q1 2025.
- · Net loss per share improved to ($0.05) from ($0.21) due to a higher share count.
27-07-2026
This S-4/A filing by Hennessy Capital Investment Corp. VII (HVII) relates to a proposed business combination with ONE Nuclear Energy LLC. The document serves as a proxy statement/prospectus for HVII shareholders to vote on the merger. The filing provides background on the transaction, risk factors, and financial information, but does not include specific financial results or performance metrics for ONE Nuclear.
- · The filing is an amendment (S-4/A) to the original registration statement (No. 333-292440).
- · The business combination agreement was entered into on October 22, 2025.
- · HVII's IPO occurred on January 21, 2025, with an over-allotment option exercised on the same date.
- · The proxy statement/prospectus includes a risk factors section and forward-looking statements.
- · Shareholders can request documents from HVII by contacting Nicholas Geeza or Advantage Proxy, Inc.
27-07-2026
Evernorth Holdings Inc. filed a 425 M&A communication regarding its proposed business combination with Armada Acquisition Corp. II and Pathfinder Digital Assets LLC, originally announced on October 19, 2025. The filing includes a recap of CEO Asheesh Birla's attendance at WebX in Tokyo and an op-ed praising Japan's new crypto regulatory framework, which classifies crypto as a financial asset, introduces insider-trading bans, and paves the way for spot crypto ETFs and a tax cut. The communication is forward-looking and does not contain financial results or period-over-period comparisons.
- · Japan's crypto reform includes an insider-trading ban, disclosure obligations, and increased maximum prison term for unregistered crypto businesses from 3 to 10 years.
- · Japan's top crypto tax rate cut from ~50% to a flat 20%, effective 2028.
- · Spot crypto ETFs targeted for listing on Tokyo Stock Exchange in 2027-2028.
- · Evernorth filed a registration statement with the SEC on March 18, 2026, which is not yet effective.
- · The business combination involves Armada Acquisition Corp. II, Evernorth Holdings Inc., Pathfinder Digital Assets LLC, and Ripple Labs Inc.
27-07-2026
Sanofi announced two key developments in July 2026: an evolution of its Executive Committee to support its next strategic chapter, and a decision not to submit amlitelimab for global regulatory reviews in atopic dermatitis. The latter represents a significant pipeline setback, while the former signals organizational changes. No financial figures were disclosed.
- · Press release dated July 21, 2026: Sanofi evolves its Executive Committee to support its next strategic chapter.
- · Press release dated July 24, 2026: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews.
27-07-2026
CEO and CFO Patel Snehal bought 2,500 Common Stock at $13.14 (~$32.9K). Patel Snehal holds 5,607,702 shares after the transaction.
- · CEO and CFO Patel Snehal bought 2,500 Common Stock at $13.14 (~$32.9K)
- · CEO and CFO Patel Snehal bought 1,100 Common Stock at $12.88 (~$14.2K)
27-07-2026
Prudential PLC repurchased 1,578,726 of its own shares on the London Stock Exchange (XLON) over five trading days from July 20 to July 24, 2026, at volume-weighted average prices ranging from £10.5069 to £11.0101 per share. The buyback activity was consistent each day, with the largest single-day purchase of 500,319 shares occurring on July 20.
- · The lowest price paid per share across the period was £10.4450 (July 20), and the highest was £11.2100 (July 22).
- · Daily purchase volumes declined from 500,319 shares on July 20 to 268,586 shares on July 24.
- · The volume-weighted average price increased from £10.5069 on July 20 to £10.9344 on July 24, with a peak of £11.0101 on July 22.
27-07-2026
BBVA disclosed that as of July 24, 2026, it has purchased shares worth €1,295,054,815.83 under the Third Tranche of its buyback program, representing 88.70% of the maximum cash amount allocated for this tranche. The transactions were executed between July 20 and July 24, 2026, with Citigroup Global Markets Europe AG acting as manager.
- · The buyback transactions were executed between July 20 and July 24, 2026.
- · The Third Tranche was initially announced in an inside information notice on April 30, 2026 (CNMV registration number 3187).
- · The buyback program is managed by Citigroup Global Markets Europe AG.
- · BBVA's LEI is K8MS7FD7N5Z2WQ51AZ71 and its ordinary shares have ISIN ES0113211835.
27-07-2026
Perfect Corp. filed a Form 6-K with the SEC on July 27, 2026, attaching a press release of its financial results for the second quarter of 2026. The filing incorporates the press release (excluding the CEO quote) into its registration statement. No specific financial figures are disclosed in the 6-K itself, so a balanced performance assessment cannot be made from this document alone.
- · The press release is dated July 27, 2026.
- · The filing incorporates Exhibit 99.1 (the press release) by reference into the Company's Registration Statement on Form F-3 (File No. 333-274835).
- · The CEO quote in the press release is excluded from incorporation by reference.
27-07-2026
SPX Technologies announced the appointment of Brian Deck as a new independent member of its Board of Directors, effective July 27, 2026. Mr. Deck, who is the CEO of JBT Marel Corporation, will also serve on the Audit and Governance & Sustainability Committees. The appointment adds a seasoned public-company CEO with a strong track record in organic and inorganic growth to the board.
- · Brian Deck is currently CEO of JBT Marel Corporation (NYSE: JBTM), a food and beverage technology solutions provider.
- · He previously served as CFO of National Material and held financial leadership roles at Ryerson, General Electric, and Bank One Corporation.
- · SPX has approximately 5,300 employees in 16 countries.
27-07-2026
Ferrari N.V. filed a Form 6-K with the SEC on July 27, 2026, furnishing a press release. The filing itself contains no financial data beyond the cover; the substantive results are in the attached press release (Exhibit 99.1). No specific metrics or performance data are available in this 6-K document, so a balanced assessment of positive and negative trends cannot be made from this filing alone.
- · Filing is a Form 6-K (foreign private issuer report) for July 2026.
- · Commission File No. 001-37596.
- · The only exhibit furnished is a press release dated July 27, 2026 (Exhibit 99.1).
- · Signed by CFO Antonio Picca Piccon.
27-07-2026
Ryanair Holdings PLC disclosed daily share buyback transactions for the week of July 20-24, 2026, repurchasing a total of 197,817 ordinary shares at volume-weighted average prices ranging from €23.7833 to €24.8139, and 83,938 ordinary shares underlying American Depositary Shares at prices between $28.1491 and $29.8376. The buyback activity was consistent across the week, with no notable spikes or declines in volume or pricing.
- · Daily ordinary share repurchases ranged from 38,434 to 41,341 shares.
- · Daily ADS-equivalent repurchases ranged from 16,248 to 17,630 shares.
- · Highest ordinary share price paid was €24.8139 on 21 July; lowest was €23.7833 on 23 July.
- · Highest ADS price paid was $29.8376 on 21 July; lowest was $28.1491 on 23 July.
27-07-2026
Apnimed, Inc. filed an S-1/A registration statement for an IPO of 10,000,000 shares (plus 1,500,000 option shares) at an assumed price of $15.00 per share, targeting net proceeds of approximately $134.6 million ($155.5 million if the underwriters' option is exercised in full). The company reported a dramatic turnaround in the first quarter of 2026, with net income of $67.7 million compared to a net loss of $28.6 million in the same period of 2025, driven by $84.8 million in related-party revenue. However, the company had a net loss of $128.2 million for the full year 2025, and its accumulated deficit stood at $329.6 million as of March 31, 2026.
- · The company's accumulated deficit was $329.6 million as of March 31, 2026.
- · Net loss from discontinued operations was $2.7 million in Q1 2026 and $70.1 million for full year 2025.
- · The company received a $100.0 million closing payment in connection with the SASS Disposition.
- · The company received $46.1 million in net proceeds from a Tranche A Term Loan from the Lenders.
- · The proposed Nasdaq Global Market symbol is 'APMD'.
- · The company had 4,793,776 weighted average basic shares outstanding in Q1 2026, increasing to 32,142,975 on a diluted basis.
- · Pro forma basic net income per share from continuing operations for Q1 2026 was $2.45; pro forma diluted was $2.12.
- · The company's working capital (pro forma as adjusted) would be $293.6 million after the offering.
27-07-2026
AstraZeneca announced positive Phase III results for sonesitatug vedotin (Sone-Ve) in CLDN18.2-positive advanced gastric/GEJ cancers. The trial met its dual primary endpoint of overall survival (OS) in 3rd/later-line and a key secondary endpoint of OS in the overall 2nd/later-line population, both with statistically significant and highly clinically meaningful improvements. However, the other dual primary endpoint of progression-free survival (PFS) showed only a trend toward improvement and did not reach statistical significance.
- · Sone-Ve has received Orphan Drug Designation from the US FDA and European Commission for gastric/GEJ cancers, and Breakthrough Designation in China for 2nd-line gastric cancer.
- · The trial included patients with CLDN18.2 expression on at least 25% of tumor cells, expanding the potential addressable population to ~60% of patients in this setting.
- · Median survival for patients receiving 2nd/later-line systemic treatments is 5-9 months.
- · Sone-Ve is being evaluated in additional Phase III (CLARITY-Gastric02) and Phase II trials across multiple GI cancers including pancreatic and biliary tract cancers.
- · AstraZeneca has a broad GI cancer pipeline including Imfinzi, Enhertu, Lynparza, Orpathys, rilvegostomig, AZD5863, AZD7003, and a pan-KRAS inhibitor programme.
27-07-2026
Chairperson & CEO ROTHBLATT MARTINE A sold 2,719 Common Stock at $532.27 (~$1.45M). 9 transactions reported in total. ROTHBLATT MARTINE A holds 324,443 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · Chairperson & CEO ROTHBLATT MARTINE A exercised/converted 9,500 Common Stock at $135.42 (~$1.29M)
- · Chairperson & CEO ROTHBLATT MARTINE A sold 820 Common Stock at $528.72 (~$434K)
- · Chairperson & CEO ROTHBLATT MARTINE A sold 2,285 Common Stock at $530.45 (~$1.21M)
- · Chairperson & CEO ROTHBLATT MARTINE A sold 1,115 Common Stock at $531.10 (~$592K)
- · Chairperson & CEO ROTHBLATT MARTINE A sold 2,719 Common Stock at $532.27 (~$1.45M)
- · Chairperson & CEO ROTHBLATT MARTINE A sold 1,818 Common Stock at $533.20 (~$969K)
- · Chairperson & CEO ROTHBLATT MARTINE A sold 630 Common Stock at $534.39 (~$337K)
- · Chairperson & CEO ROTHBLATT MARTINE A sold 113 Common Stock at $535.03 (~$60.5K)
27-07-2026
Neumora Therapeutics announced favorable pre-clinical toxicology results for NMRA-215 on July 27, 2026. The positive safety data supports the advancement of this candidate, though no financial figures or period-over-period comparisons were provided in the filing.
- · Favorable pre-clinical toxicology results for NMRA-215 were announced.
- · The press release is filed as Exhibit 99.1 to the 8-K.
27-07-2026
MapLight Therapeutics, Inc. (MPLT) announced topline results from the ZEPHYR Phase 2 trial of ML-007C-MA in inpatient adults with schizophrenia experiencing acute psychosis on July 27, 2026. The company held a conference call and issued a press release detailing the results. No specific financial or quantitative trial data is provided in this 8-K filing.
- · The ZEPHYR trial is a Phase 2 study of ML-007C-MA in inpatient adult participants with schizophrenia experiencing an acute exacerbation of psychosis.
- · The company furnished a presentation (Exhibit 99.1) and filed a press release (Exhibit 99.2) with the SEC.
- · MapLight Therapeutics is an emerging growth company and has not elected to use the extended transition period for complying with new financial accounting standards.
27-07-2026
AstraZeneca announced that its Phase III trial of Ultomiris (ravulizumab) in adults and adolescents with HSCT-TMA did not meet the primary endpoint of event-free survival through 26 weeks. However, a separate Phase III trial in pediatric patients showed clinically meaningful overall survival of 87.2% at 26 weeks and 73.4% at 52 weeks. The company is advancing regulatory filings for the pediatric indication while continuing discussions with health authorities regarding the adult data.
- · The primary endpoint of ALXN1210-TMA-313 (event-free survival through 26 weeks) was not statistically significant for Ultomiris vs placebo.
- · Ultomiris showed a trend toward treatment benefit in adults and adolescents at 26 weeks.
- · Ultomiris has Orphan Drug Designation in the US and Japan for HSCT-TMA and Breakthrough Therapy designation from the US FDA for pediatric HSCT-TMA.
- · The safety profile in both trials was consistent with the known safety profile of Ultomiris and with patients undergoing HSCT.
- · HSCT-TMA is estimated to affect fewer than 6,000 people in the US.
- · One-year survival rates in pediatric HSCT-TMA patients are estimated between 17% and 44% based on scientific literature.
27-07-2026
XCF Global, Inc. filed a preliminary proxy statement on July 27, 2026, in connection with a special meeting of stockholders to vote on proposals related to its business combination with DevvStream Corp. and Southern Energy Renewables Inc. The proposals include increasing authorized Class A common stock from 500,000,000 to 1,700,000,000 shares, approving the issuance of 19.99% or more of outstanding stock as consideration, electing seven directors, and increasing the equity incentive plan from 14,557,181 to 80,000,000 shares. The record date for the special meeting is July 29, 2026.
- · The filing is a preliminary proxy statement and soliciting material under Rule 14a-12.
- · The business combination agreement was dated April 13, 2026.
- · The company is an emerging growth company and has not elected to use the extended transition period for new accounting standards.
- · The company's common stock trades on Nasdaq under the symbol SAFX.
Get daily alerts with 11 investment signals, 9 risk alerts, 9 opportunities and full AI analysis of all 50 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US SEC Filings Daily Market Digest
🇺🇸 More from United States
View all →July 28, 2026
US Pre-Market SEC Filings Roundup — July 28, 2026
US Pre-Market SEC Filings Roundup
July 28, 2026
US Merger & Acquisition SEC Filings — July 28, 2026
US Merger & Acquisition SEC Filings
July 28, 2026
USA Insider Trading Pulse — July 28, 2026
USA Insider Trading Pulse
July 28, 2026
US Corporate Board Director Changes SEC Filings — July 28, 2026
US Corporate Board Director Changes SEC Filings